Prospective Single-arm, Single-center Clinical Study of Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Regimen in Relapsed/Refractory Patients With Diffuse Large B-cell Lymphoma
Latest Information Update: 14 Jul 2023
At a glance
- Drugs Polatuzumab vedotin (Primary) ; Rituximab (Primary) ; Zanubrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 14 Jul 2023 New trial record